By Reneo Pharmaceuticals, based in Irvine, Calif., recently announced that it will be making significant changes to its operations following disappointing results from a trial of its treatment for mitochondrial myopathies, mavodelpar. The company plans to reduce its headcount by approximately 70% and implement cost-cutting measures in response to the trial’s failure to meet both primary and secondary efficacy endpoints.
Trial Results Fall Short of Expectations
The study focused on adult patients with primary mitochondrial myopathies, a group of diseases that are known to cause muscle problems. Unfortunately, during a 12-minute walk test at week 24, mavodelpar did not demonstrate the desired change from baseline that would meet the trial’s primary endpoint. Additionally, the intervention did not result in the anticipated change from baseline in a short-form fatigue test, which served as the secondary endpoint.
Immediate Response and Future Plans
To address this setback, Reneo Pharmaceuticals has formulated a plan to swiftly implement cost savings initiatives. This includes a significant reduction in its workforce and the temporary suspension of mavodelpar’s development. By taking these actions, the company aims to streamline its operations and allocate resources more efficiently.
Commitment to Scientific Community
Despite the disappointing outcome of the trial, Reneo Pharmaceuticals remains committed to transparency and collaboration within the scientific community. Once the final analyses are completed, the company will make the data available for further scrutiny and evaluation.
Comments